Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 406 to 420 of 490 results for %s

  1. Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments (TA930)

    Evidence-based recommendations on lutetium-177 vipivotide tetraxetan (Pluvicto) for treating prostate-specific membrane antigen-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments in adults.

  2. Early years: promoting health and wellbeing in under 5s (QS128)

    This quality standard covers services to support the health, and social and emotional wellbeing of children under 5, including vulnerable children who may need extra support. It includes health visitor services, childcare and early years education, and early intervention services in children’s social care. It describes high-quality care in priority areas for improvement.

  3. ImmunoCAP ISAC 112 for multiplex allergen testing (HTG413)

    Evidence-based recommendations on multiplex allergen testing, using ImmunoCAP ISAC 112 in people with allergy that is difficult to diagnose.

  4. Radiation therapy for early Dupuytren's disease (HTG427)

    Evidence-based recommendations on radiation therapy for early Dupuytren’s contractures in adults. This involves directing low energy X-rays at the affected tissue.

  5. Cryotherapy for malignant endobronchial obstruction (HTG89)

    Evidence-based recommendations on cryotherapy for malignant endobronchial obstruction. This involves using cold temperatures to destroy the cancer tissue that’s causing a blockage.

  6. Leukapheresis for inflammatory bowel disease (HTG75)

    Evidence-based recommendations on leukapheresis for inflammatory bowel disease. This involves removing a small number of white blood cells from the person’s blood.

  7. EDI roadmap and annual action plan

    NICE's equality, diversity, and inclusion roadmap and annual action plan - committed to creating a forward-looking, positive work culture where everyone can thrive.

  8. Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women (TA160)

    Evidence-based recommendations on raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women.

  9. Harmful sexual behaviour among children and young people (NG55)

    This guideline covers children and young people who display harmful sexual behaviour, including those on remand or serving community or custodial sentences. It aims to ensure these problems don’t escalate and possibly lead to them being charged with a sexual offence. It also aims to ensure no-one is unnecessarily referred to specialist services.

  10. Narrow band imaging for Barrett's oesophagus (MIB179)

    NICE has developed a medtech innovation briefing (MIB) on narrow band imaging for Barrett’s oesophagus .

  11. Ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections (AMR1)

    Evidence-based recommendations on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections.

  12. Cefiderocol for treating severe drug-resistant gram-negative bacterial infections (AMR2)

    Evidence-based recommendations on cefiderocol for treating severe drug-resistant gram-negative bacterial infections.

  13. Consultancy service

    Get expert advice and support from NICE International, part of the UK's National Institute for Health and Care Excellence, for a project in your country

  14. Therapeutic monitoring of TNF-alpha inhibitors in Crohn's disease (LISA-TRACKER ELISA kits, IDKmonitor ELISA kits, and Promonitor ELISA kits) (HTG401)

    Evidence-based recommendations on therapeutic monitoring of tumour necrosis factor (TNF)-alpha inhibitors (LISA-TRACKER, IDKmonitor and Promonitor ELISA kits) in people with Crohn’s disease.

  15. Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (TA161)

    Evidence-based recommendations on raloxifene and teriparatide for preventing osteoporotic fragility fractures in postmenopausal women who have osteoporosis.